The Growth Hormone Decline Problem
Growth hormone (GH) is not just for children. In adults, GH plays a critical role in body composition, metabolic health, sleep quality, cognitive function, bone density, and cellular repair. The problem is that GH secretion declines significantly with age — dropping roughly 14% per decade after the age of 30, and often accelerating in midlife.
By the time most adults reach their 40s, GH output is a fraction of what it was in their 20s. The downstream effects include increased visceral fat, reduced muscle mass, slower recovery from exercise, poor sleep architecture, and declining skin and connective tissue quality — all hallmarks of what we recognise as biological ageing.
GH-releasing peptides offer a fundamentally different approach to addressing this decline compared to exogenous HGH — one that works with the body's own regulatory systems rather than bypassing them.
What Are Ipamorelin and CJC-1295?
Ipamorelin — The Selective GHRP
Ipamorelin is a synthetic pentapeptide (5 amino acids) and a selective growth hormone-releasing peptide (GHRP). It mimics the action of ghrelin — the "hunger hormone" — on the pituitary gland's ghrelin receptors (GHS-R1a), triggering a GH pulse. Its key distinguishing feature is selectivity: unlike older GHRPs such as GHRP-2 and GHRP-6, Ipamorelin does not significantly stimulate cortisol or prolactin release. This selectivity makes it a cleaner, better-tolerated option with fewer hormonal side effects.
Ipamorelin produces GH pulses that mirror the body's natural pulsatile secretion pattern, making it one of the most physiologically appropriate GHRPs available.
CJC-1295 — The GHRH Analogue
CJC-1295 is a synthetic analogue of GHRH (growth hormone-releasing hormone) — the hypothalamic signal that tells the pituitary to release GH. It binds to GHRH receptors on pituitary somatotroph cells, amplifying and extending the GH pulse. The version with DAC (Drug Affinity Complex) has a significantly longer half-life (approximately 6–8 days) due to its ability to bind albumin, allowing less frequent dosing.
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) has a shorter half-life of approximately 30 minutes and is more commonly used in combination protocols to produce a sharper, more defined GH pulse.
Why They Are Used Together
Ipamorelin and CJC-1295 act on two different receptor pathways. Used together, they create a synergistic effect — producing a stronger GH pulse than either compound alone, while maintaining the physiological pulsatile release pattern. The combination is the most widely used peptide protocol in clinical anti-ageing and sports medicine practice.
Ipamorelin
- Acts on GHS-R1a (ghrelin receptor)
- Selective — minimal cortisol/prolactin stimulation
- Short half-life (~2 hours)
- Produces sharp, clean GH pulse
- Daily or twice-daily injection typically
CJC-1295 (no DAC)
- Acts on GHRH receptors (pituitary)
- Amplifies and extends the GH pulse
- Short half-life (~30 minutes)
- Synergistic when combined with Ipamorelin
- Typically co-injected with Ipamorelin
Clinical Benefits: What the Evidence Shows
Sleep Quality
GH is primarily released during slow-wave (deep) sleep. Restoring GH pulses via peptides consistently improves sleep depth and duration in studies and clinical reports.
Body Composition
GH stimulates lipolysis (fat breakdown) — particularly visceral fat — and supports lean muscle preservation. Patients typically report improved body composition over 3–6 months.
Muscle Recovery
GH accelerates muscle protein synthesis and reduces exercise-induced muscle damage. Athletes report faster recovery between sessions and reduced DOMS.
Bone Density
GH stimulates IGF-1 production in the liver, which directly promotes osteoblast activity and bone mineralisation. Important for adults over 40 at risk of osteopenia.
Skin & Collagen
GH and IGF-1 stimulate collagen and elastin synthesis. Improvements in skin thickness, elasticity, and wound healing are consistently reported.
Cognitive Function
GH receptors are present throughout the brain. GH deficiency in adults is associated with cognitive fog, depression, and reduced quality of life — all of which can improve with restoration.
Ipamorelin vs CJC-1295 vs Synthetic HGH
It is essential to understand how GH-releasing peptides differ from injectable synthetic human growth hormone (HGH), which is a licensed medicine in the UK for specific deficiency indications.
| Feature | Ipamorelin + CJC-1295 | Synthetic HGH |
|---|---|---|
| Mechanism | Stimulates pituitary to release own GH | Directly replaces GH via injection |
| Feedback regulation | Preserved — body's somatostatin still provides a ceiling | Bypassed — no natural brake on GH levels |
| GH release pattern | Pulsatile (physiological) | Constant elevation (non-physiological) |
| Pituitary suppression | None — pituitary remains active | Yes — prolonged use suppresses pituitary GH production |
| IGF-1 elevation | Moderate, physiological | Can be supraphysiological — higher risk of side effects |
| Cancer risk concern | Lower — physiological IGF-1 levels maintained | Higher at supraphysiological doses — IGF-1 is growth-promoting |
| UK regulatory status | Not MHRA-licensed; prescribable as specials | MHRA-licensed for GH deficiency (Norditropin, Genotropin etc.) |
| Cost | Significantly lower | Very high (£500–£2,000+/month for HGH) |
Dosing Protocols
The following represents commonly referenced preclinical and anecdotal clinical dosing. No standardised human clinical dosing exists. All protocols must be supervised by a qualified physician.
| Parameter | Ipamorelin | CJC-1295 (no DAC) |
|---|---|---|
| Typical dose | 100–300 mcg per injection | 100–300 mcg per injection |
| Frequency | 1–3× daily | Co-injected with Ipamorelin (same frequency) |
| Timing | Before bed (largest pulse aligns with sleep), or pre-workout | Same timing as Ipamorelin |
| Cycle duration | 8–24 weeks typically | Same |
| Administration route | Subcutaneous injection (abdomen, thigh, deltoid) | Subcutaneous injection |
| Fasting requirement | Best taken 2 hours after food (insulin blunts GH response) | Same |
Blood Test Monitoring Protocol
IGF-1 is the primary laboratory marker used to monitor GH-releasing peptide therapy. IGF-1 is produced by the liver in response to GH stimulation and has a longer half-life than GH itself, making it a far more stable and practical measurement. The goal is to keep IGF-1 within the upper-normal range for your age — not to drive it supraphysiological.
| Test | Purpose | When |
|---|---|---|
| IGF-1 | Primary marker of GH activity. Target: 150–300 ng/mL (age-adjusted). If elevated above 300–350 ng/mL, dose should be reduced. | Baseline, then every 6–8 weeks |
| Fasting glucose & HbA1c | GH causes insulin resistance; elevated fasting glucose is a key safety concern | Baseline, then every 8 weeks |
| Fasting insulin | HOMA-IR (insulin resistance index): fasting glucose × fasting insulin ÷ 22.5. Target HOMA-IR <2.5 | Baseline, then every 8 weeks |
| Thyroid function (TSH, fT4, fT3) | GH influences T4-to-T3 conversion; subclinical hypothyroidism can blunt the benefits of peptide therapy | Baseline, then every 12 weeks |
| Cortisol (AM serum) | Ipamorelin has minimal cortisol effect, but baseline cortisol is important context for fatigue and body composition goals | Baseline |
| Prolactin | Ipamorelin has minimal prolactin effect compared to GHRP-2/6, but baseline and 8-week check are prudent | Baseline, then at 8 weeks |
| LFTs, FBC, renal profile | General safety monitoring | Baseline, then at 12 weeks |
| Testosterone (if male) | GH and testosterone have complementary anabolic effects; total and free testosterone are useful context | Baseline |
IGF-1 Reference Ranges by Age
| Age Group | Normal IGF-1 Range (ng/mL) | Optimal Therapeutic Target |
|---|---|---|
| 20–29 | 182–780 | Upper half of normal (350–500+) |
| 30–39 | 114–492 | 250–400 |
| 40–49 | 90–360 | 200–300 |
| 50–59 | 71–290 | 180–270 |
| 60–69 | 58–240 | 150–230 |
| 70+ | 35–175 | 120–175 |
Reference ranges vary by laboratory. Always interpret IGF-1 in the context of your laboratory's specific reference range and your clinical picture.
Side Effects & Safety Considerations
Ipamorelin and CJC-1295 are generally well-tolerated. Reported side effects include:
- Water retention — temporary fluid retention in the first 1–2 weeks as GH increases, which resolves spontaneously
- Injection site reactions — mild redness or bruising at the injection site, typically resolving within 24 hours
- Increased hunger — Ipamorelin acts on ghrelin receptors; some patients experience transient increased appetite, particularly after the pre-bedtime dose
- Mild headache or tingling — occasionally reported in the first week, thought to relate to GH-induced changes in fluid balance
- Insulin resistance — the most clinically significant concern with any GH-stimulating therapy. Regular fasting glucose monitoring is non-negotiable
Frequently Asked Questions
What is the difference between Ipamorelin and CJC-1295?
Ipamorelin mimics ghrelin to trigger GH release from the pituitary. CJC-1295 mimics GHRH to amplify and extend that pulse. They work on complementary pathways — Ipamorelin creates the pulse, CJC-1295 amplifies it. Used together they produce a stronger, more physiological GH release than either compound alone.
Is growth hormone peptide therapy the same as taking HGH?
No — they are fundamentally different. Exogenous synthetic HGH bypasses the body's own feedback mechanisms and suppresses natural GH production. GH-releasing peptides stimulate the pituitary to release its own GH in natural pulses, preserving the somatostatin feedback system. This makes peptides a safer and more physiological approach.
What blood tests do I need before starting?
Essential baseline tests include: IGF-1, fasting glucose and HbA1c, fasting insulin, thyroid function (TSH, fT4, fT3), cortisol, prolactin, FBC, LFTs, and renal profile. If male, include testosterone. IGF-1 should be monitored every 6–8 weeks during the protocol to keep levels within the optimal age-adjusted range.